- Home
- DXST vs INAB Comparison
DXST vs INAB Comparison
Compare DXST & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXST
- INAB
- Stock Information
- Founded
- DXST 2011
- INAB 2016
- Country
- DXST China
- INAB United States
- Employees
- DXST N/A
- INAB N/A
- Industry
- DXST
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- DXST
- INAB Health Care
- Exchange
- DXST NYSE
- INAB Nasdaq
- Market Cap
- DXST 21.4M
- INAB 18.8M
- IPO Year
- DXST 2025
- INAB 2021
- Fundamental
- Price
- DXST $1.41
- INAB $0.27
- Analyst Decision
- DXST
- INAB Strong Buy
- Analyst Count
- DXST 0
- INAB 3
- Target Price
- DXST N/A
- INAB $5.57
- AVG Volume (30 Days)
- DXST 366.4K
- INAB 14.2M
- Earning Date
- DXST 01-01-0001
- INAB 03-13-2025
- Dividend Yield
- DXST N/A
- INAB N/A
- EPS Growth
- DXST N/A
- INAB N/A
- EPS
- DXST N/A
- INAB N/A
- Revenue
- DXST $4,333,276.00
- INAB N/A
- Revenue This Year
- DXST N/A
- INAB N/A
- Revenue Next Year
- DXST N/A
- INAB N/A
- P/E Ratio
- DXST N/A
- INAB N/A
- Revenue Growth
- DXST N/A
- INAB N/A
- 52 Week Low
- DXST $1.21
- INAB $0.22
- 52 Week High
- DXST $5.74
- INAB $1.74
- Technical
- Relative Strength Index (RSI)
- DXST N/A
- INAB 47.53
- Support Level
- DXST N/A
- INAB $0.25
- Resistance Level
- DXST N/A
- INAB $0.30
- Average True Range (ATR)
- DXST 0.00
- INAB 0.04
- MACD
- DXST 0.00
- INAB 0.00
- Stochastic Oscillator
- DXST 0.00
- INAB 19.95
About DXST DECENT HOLDING INC
Decent Holding Inc through its subsidiary specializes in the provision of wastewater treatment by cleansing the industrial wastewater, ecological river restoration and river ecosystem management by enhancing the water quality, as well as microbial products used for pollutant removal and water quality enhancement. Its main services and products include (1) wastewater treatment, (2) river water quality management, and (3) microbial products for water quality enhancement and pollutant cleansing purposes. The company's focus is on research and development (R&D) to sharpen its innovation edge.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.